当前位置： SCI文献检索 > UROLOGY期刊下所有文献 > Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.

Abstract：

OBJECTIVES:To examine the safety, efficacy, and tolerability of tolterodine in four randomized, double-blind, parallel, multicenter, 12-week studies of patients with overactive bladder. METHODS:Two of the four studies compared tolterodine (2 mg twice daily) to oxybutynin (5 mg three times daily) and placebo, one study compared tolterodine (2 mg twice daily) to oxybutynin (5 mg three times daily), and one study compared two dosages of tolterodine (1 and 2 mg twice daily) to placebo. Efficacy was determined from micturition diaries and patient perception of their bladder condition. Safety and tolerability were assessed from adverse events and laboratory measures. RESULTS:A total of 1,120 patients were randomized and treated at 134 centers. For the primary efficacy variable, the number of micturitions/24 hours, pooled results showed a significant decrease from baseline for the 1 mg tolterodine (P < 0.001), 2 mg tolterodine (P < 0.001), and 5 mg oxybutynin (P < 0.01) groups, compared to placebo. Both tolterodine doses and oxybutynin significantly decreased incontinence episodes/24 hours and significantly increased volume voided/micturition, compared to placebo. Tolterodine at a dose of 2 mg twice daily and 5 mg oxybutynin twice daily were significantly more effective in improving patient perception of bladder condition than placebo. Tolterodine at a dose of 2 mg and 5 mg oxybutynin were equivalent in their effectiveness. Tolterodine at doses of 1 mg and 2 mg were tolerated significantly better than oxybutynin when adverse events, dry mouth (both frequency and intensity), dose reductions, and patient withdrawals were considered. CONCLUSIONS:Although oxybutynin is highly effective, its clinical utility is limited by systemic side effects that lead to frequent discontinuation of treatment or dose reductions. Patients receiving tolterodine should not experience these limitations and instead will get safe and long-term effective treatment for their condition.

journal_name

Urology

journal_title

Urology

authors

Appell RA

doi

10.1016/s0090-4295(97)00599-2

subject

Has Abstract

pub_date

1997-12-01 00:00:00

pages

90-6; discussion 97-9

issue

6A Suppl

eissn

0090-4295

issn

1527-9995

pii

S0090-4295(97)00599-2

journal_volume

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

在线工具

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.